

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI657666

<b>SUBMISSION TYPE:</b>	RESUBMISSION
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>RESUBMIT DOCUMENT ID:</b>	508772271
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Cero Therapeutics, Inc.	09/20/2024
<b>RECEIVING PARTY DATA</b>	
<b>Company Name:</b>	Cero Therapeutics Holdings, Inc.
<b>Street Address:</b>	201 Haskins Way
<b>Internal Address:</b>	Suite 230
<b>City:</b>	South San Francisco
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	94080
<b>PROPERTY NUMBERS Total: 71</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	62400578
Application Number:	62445235
Application Number:	16334224
Application Number:	17400082
Application Number:	18304206
Application Number:	18527075
Application Number:	17481150
Application Number:	17812653
Application Number:	18322450
Application Number:	17031881
Application Number:	17156445
Application Number:	17543567
Application Number:	17330258
Application Number:	17683190
Application Number:	62563615
Application Number:	62652822
Application Number:	16367221
Application Number:	16900752

Property Type	Number
Application Number:	62649529
Application Number:	16672345
Application Number:	16375846
Application Number:	16646530
Application Number:	16785485
Application Number:	17040317
Application Number:	62649491
Application Number:	62649472
Application Number:	17040341
Application Number:	62649499
Application Number:	17040464
Application Number:	17040472
Application Number:	62649541
Application Number:	62734863
Application Number:	62652838
Application Number:	63066098
Application Number:	62910133
Application Number:	17766173
Application Number:	17154959
Application Number:	62964105
Application Number:	63066149
Application Number:	18041198
Application Number:	63172057
Application Number:	63226736
Application Number:	18418120
Application Number:	18041195
Application Number:	63226643
Application Number:	63066085
Application Number:	63066150
Application Number:	63226712
Application Number:	63087049
Application Number:	18041200
Application Number:	63311016
Application Number:	63311045
Application Number:	63311042
Application Number:	63342031
Application Number:	63336980
Application Number:	18292782

Property Type	Number
Application Number:	63341999
Application Number:	63336972
Application Number:	63311043
Application Number:	18787533
PCT Number:	US1753553
PCT Number:	US1852297
PCT Number:	US1924435
PCT Number:	US1924433
PCT Number:	US1924441
PCT Number:	US1924442
PCT Number:	US2054153
PCT Number:	US2146043
PCT Number:	US2146014
PCT Number:	US2146041
PCT Number:	US2274281

#### CORRESPONDENCE DATA

**Fax Number:** 2063891708

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** (206)6243600

**Email:** abrewer@foxrothschild.com,SeattleIP@foxrothschild.com

**Correspondent Name:** Alexis Brewer

**Address Line 1:** 1001 Fourth Avenue

**Address Line 2:** Suite 4400

**Address Line 4:** Seattle, WASHINGTON 98154

<b>ATTORNEY DOCKET NUMBER:</b>	368779
<b>NAME OF SUBMITTER:</b>	Alexis Brewer
<b>SIGNATURE:</b>	Alexis Brewer
<b>DATE SIGNED:</b>	11/27/2024

#### Total Attachments: 14

source=Cero Therapeutics Holdings - Assignment#page1.tiff

source=Cero Therapeutics Holdings - Assignment#page2.tiff

source=Cero Therapeutics Holdings - Assignment#page3.tiff

source=Cero Therapeutics Holdings - Assignment#page4.tiff

source=Cero Therapeutics Holdings - Assignment#page5.tiff

source=Cero Therapeutics Holdings - Assignment#page6.tiff

source=Cero Therapeutics Holdings - Assignment#page7.tiff

source=Cero Therapeutics Holdings - Assignment#page8.tiff

source=Cero Therapeutics Holdings - Assignment#page9.tiff

source=Cero Therapeutics Holdings - Assignment#page10.tiff

source=Cero Therapeutics Holdings - Assignment#page11.tiff

source=Cero Therapeutics Holdings - Assignment#page12.tiff

source=Cero Therapeutics Holdings - Assignment#page13.tiff

source=Cero Therapeutics Holdings - Assignment#page14.tiff

**PATENT**

**REEL: 069436 FRAME: 0940**

## ASSIGNMENT

**Cero Therapeutics, Inc.** (referred to as “ASSIGNOR”), having an address of 201 Haskins Way, Suite 230, South San Francisco, CA 94080, is an inventor or owner of one or more inventions described in the application(s) listed in Appendix A (referred to as the “Application(s)):

**Cero Therapeutics Holdings, Inc.** (referred to as “ASSIGNEE”), having an address of 201 Haskins Way, Suite 230, South San Francisco, California 94080 is desirous of acquiring ASSIGNOR’s entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent which may be granted for the Application(s) and for any application claiming priority to any of the Application(s) in the United States and in any and all foreign jurisdictions.

In exchange for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby sells, assigns, and transfers, or confirms the previous sale, assignment, and transfer, by law, agreement, or otherwise, to ASSIGNEE, ASSIGNOR’s entire right, title, and interest in and to the one or more inventions, the Application(s), and any letters patent that may be granted for the Application(s), and for any application claiming priority to any of the Application(s) in the United States and all foreign jurisdictions, including any extensions or adjustments in term thereof, including divisions, continuations, continuations-in-part, and reissues thereof, including the right to file applications directly in the name of ASSIGNEE and to claim priority to any of the Application(s) and any application claiming priority to any of the Application(s) in the United States and in all foreign jurisdictions under any applicable legislation, convention, treaty, or otherwise, and further including the right to sue and obtain legal and equitable relief, including damages, profits, and injunctions, for past, present, and future infringement of any letters patent that may be granted for the Application(s) and for any application claiming priority to any of the Application(s); the Application(s), any application claiming priority to any of the Application(s), and any letters patent that may be granted for the Application(s) or for any application claiming priority to any of the Application(s) to be held and enjoyed by ASSIGNEE and their successors and assigns for their use and benefit as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had the sale, assignment, and transfer not been executed.

ASSIGNOR hereby authorizes the relevant authority to issue all letters patent on the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.

ASSIGNOR agrees to execute all instruments required for the filing and prosecution of the Application(s) and any application claiming priority to any of the Application(s), for litigation regarding any letters patent, or for the purpose of protecting title to the Application(s), or any application claiming priority to any of the Application(s), and any and all letters patent granted therefor. In the event the present Assignment is determined to be ineffective with respect to any portion of ASSIGNOR's right, title, and interest in and to the Application(s) or any application claiming priority to any of the Application(s), ASSIGNOR agrees to assign ASSIGNOR's entire right, title, and interest in and to the Application(s) and any application claiming priority to any of the Application(s) to ASSIGNEE.

ASSIGNOR hereby authorizes Fox Rothschild LLP to insert the jurisdiction(s), application number(s), filing date(s), patent number(s), issue date(s), and title(s) of the Application(s) and any application claiming priority to any of the Application(s) in Appendix A.

**Cero Therapeutics, Inc.**

Date: 09/20/24

DocuSigned by:  
Daniel Corey (ASSIGNOR)  
01560D1E2A7741A...  
Signature

Daniel Mark Corey, Chief Executive Officer  
Printed Name, Title

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California

County of \_\_\_\_\_

On \_\_\_\_\_, before me, \_\_\_\_\_,  
(Here insert name and title of the officer)

personally appeared \_\_\_\_\_,  
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.


WITNESS my hand and official seal.

\_\_\_\_\_  
Signature of Notary Public

(Notary Seal)

**Cero Therapeutics Holdings, Inc.**

Date: 09/20/24

Signed by:   
11ABB3FDE7794C6... (ASSIGNEE)  
Signature

Brian G. Atwood, Chief Executive Officer  
Printed Name, Title



## Appendix A:

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
62/400578	US	27-Sep-2016	CHIMERIC PHAGOCYTIC SWITCH MOLECULES
62/445235	US	11-Jan-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
PCT/US2017/053553	WO	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
2017335634	AU	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
265606	IL	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
2019-538094	JP	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
201917007358	IN	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
201780073281.5	CN	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
2019112860	RU	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
62020002217.1	HK	04-Feb-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
16/334224	US	18-Mar-2019	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
MX/a/2019/003489	MX	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	EP	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
3035080	CA	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
751042	NZ	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
62020001489.7	HK	15-Jan-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
10-2019-7009535	KR	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17/400082	US	11-Aug-2021	CHIMERIC ENGULFMENT RECEPTOR MOLECULES

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
22163514.7	EP	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	ES	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	GB	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
2022-209575	JP	26-Sep-2016	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
18/304206	US	20-Apr-2023	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	FR	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
18/527075	US	01-Dec-2023	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	DE	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17857294.7	IT	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES
17/481150	US	21-Sep-2021	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
2023-085311	JP	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/812653	US	14-Jul-2022	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
18/322450	US	23-May-2023	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/031881	US	24-Sep-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
62021024878.2	HK	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/156445	US	22-Jan-2021	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/543567	US	06-Dec-2021	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/330258	US	25-May-2021	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
62020022702.8	HK	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
3073421	CA	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
762269	NZ	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/683190	US	28-Feb-2022	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
62/563615	US	26-Sep-2017	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
62/652822	US	04-Apr-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/367221	US	27-Mar-2019	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
202017014731	IN	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/900752	US	12-Jun-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
62/649529	US	28-Mar-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
201880076426.1	CN	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
PCT/US2018/052297	WO	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/672345	US	01-Nov-2019	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
18822166.7	EP	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
2020114641	RU	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
272803	IL	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/375846	US	04-Apr-2019	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/646530	US	11-Mar-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
10-2020-7008130	KR	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
16/785485	US	07-Feb-2020	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
2020-538755	JP	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
2018341244	AU	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
MX/a/2020/007266	MX	21-Sep-2018	CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE
17/040317	US	22-Sep-2020	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
62/649491	US	28-Mar-2018	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
PCT/US2019/024435	WO	27-Mar-2019	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
62021036349.0	HK	27-Mar-2019	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
19718874.1	EP	27-Mar-2019	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
19718873.3	EP	27-Mar-2019	CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES
62/649472	US	28-Mar-2018	CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES
17/040341	US	22-Sep-2020	CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES
PCT/US2019/024433	WO	27-Mar-2019	CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF FOR NEURODEGENERATIVE DISEASES
62/649499	US	28-Mar-2018	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
2019243153	AU	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
MX/a/2020/010235	MX	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
201980035719.X	CN	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
2020135106	RU	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
PCT/US2019/024441	WO	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
2020-552225	JP	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
62021036350.8	HK	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
10-2020-7029512	KR	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
17/040464	US	22-Sep-2020	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
18/787,533	US	29-Jul-2024	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
3093969	CA	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
768237	NZ	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
277587	IL	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
202017046174	IN	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
19725783.5	EP	27-Mar-2019	EXPRESSION VECTORS FOR CHIMERIC ENGULFMENT RECEPTORS, GENETICALLY MODIFIED HOST CELLS, AND USES THEREOF
2019243154	AU	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
MX/a/2020/010241	MX	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
62021036351.6	HK	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
201980036210.7	CN	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
2020135107	RU	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
3093973	CA	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
768238	NZ	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
2020-551824	JP	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
277584	IL	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
19718875.8	EP	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
10-2020-7030662	KR	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
202017046683	IN	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
17/040472	US	22-Sep-2020	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
PCT/US2019/024442	WO	27-Mar-2019	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
62/649541	US	28-Mar-2018	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF

<b>Application No.</b>	<b>Jurisdiction</b>	<b>Filing Date (DD/MM/YYYY)</b>	<b>Title</b>
62/734863	US	21-Sep-2018	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
62/652838	US	04-Apr-2018	CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF
63/066098	US	14-Aug-2020	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
PCT/US2020/054153	WO	02-Oct-2020	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
62/910133	US	03-Oct-2019	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
20796995.7	EP	02-Oct-2020	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
17/766173	US	01-Apr-2022	CHIMERIC TIM4 RECEPTORS AND USES THEREOF
17/154959	US	21-Jan-2021	BIVALENT CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF
62/964105	US	21-Jan-2020	BIVALENT CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF
63/066149	US	14-Aug-2020	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
PCT/US2021/046043	WO	13-Aug-2021	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
21777885.1	EP	13-Aug-2021	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
18/041198	US	09-Feb-2023	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
3189482	CA	13-Aug-2021	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
63/172057	US	07-Apr-2021	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
63/226736	US	28-Jul-2021	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
18/418120	US	19-Jan-2024	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
PCT/US2021/046014	WO	13-Aug-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF
2023-510470	JP	13-Aug-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
202180069977.7	CN	13-Aug-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF
18/041195	US	09-Feb-2023	CHIMERIC TIM RECEPTORS AND USES THEREOF
21778593.0	EP	13-Aug-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF
3189328	CA	13-Aug-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF
63/226643	US	28-Jul-2021	CHIMERIC TIM RECEPTORS AND USES THEREOF
63/066085	US	14-Aug-2020	CHIMERIC TIM RECEPTORS AND USES THEREOF
63/066150	US	14-Aug-2020	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
2023-510448	JP	13-Aug-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
202180070365.X	CN	13-Aug-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
63/226712	US	28-Jul-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
PCT/US2021/046041	WO	13-Aug-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
63/087049	US	02-Oct-2020	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE



Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
18/041200	US	09-Feb-2023	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
21778257.2	EP	13-Aug-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
3189480	CA	13-Aug-2021	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
63/311016	US	16-Feb-2022	COMPOSITIONS AND METHODS FOR ENHANCING CCR7 EXPRESSING T CELLS OR CD4/CD8 T CELL RATIO WITH CHIMERIC TIM4 RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE
63/311045	US	16-Feb-2022	ANTI-CD72 CHIMERIC RECEPTORS AND USES THEREOF
63/311042	US	16-Feb-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
63/342031	US	13-May-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
63/336980	US	29-Apr-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
2024-505181	JP	28-Jul-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
18/292782	US	26-Jan-2024	CHIMERIC TIM RECEPTORS AND USES THEREOF
10-2024-7006676	KR	28-Jul-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
22758100.6	EP	28-Jul-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
PCT/US2022/074281	WO	28-Jul-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF
202280065559.5	CN	28-Jul-2022	CHIMERIC TIM RECEPTORS AND USES THEREOF

Application No.	Jurisdiction	Filing Date (DD/MM/YYYY)	Title
63/341999	US	13-May-2022	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE
63/336972	US	29-Apr-2022	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE
63/311043	US	16-Feb-2022	COMPOSITIONS AND METHODS FOR TREATING CANCER WITH CHIMERIC TIM RECEPTORS IN COMBINATION WITH INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE

368779.00001 /

14

161563477.1